221 related articles for article (PubMed ID: 15704289)
1. COX-2 inhibitors: cancer prevention or cardiovascular risk?
Senior K
Lancet Oncol; 2005 Feb; 6(2):68. PubMed ID: 15704289
[No Abstract] [Full Text] [Related]
2. COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM
N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
[No Abstract] [Full Text] [Related]
3. COX-2 inhibitors--lessons in drug safety.
Psaty BM; Furberg CD
N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
[No Abstract] [Full Text] [Related]
4. Differences between COX-2-specific inhibitors: clinical and economic implications.
Sonnenblick EH
Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792
[No Abstract] [Full Text] [Related]
5. [Thinking about the specific cyclooxygenase-2 inhibitors since its recommendation].
Shi G
Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):579-80. PubMed ID: 11758234
[No Abstract] [Full Text] [Related]
6. Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer.
Sharma RA
QJM; 2002 May; 95(5):267-73. PubMed ID: 11978897
[No Abstract] [Full Text] [Related]
7. COX-2 inhibitors and cardiovascular toxicity: a class effect?
Laible B
S D J Med; 2005 Mar; 58(3):93-4. PubMed ID: 15794479
[No Abstract] [Full Text] [Related]
8. COX-2 inhibitors still eyed for cancer prevention.
Thompson CA
Am J Health Syst Pharm; 2005 May; 62(9):890, 894. PubMed ID: 15851492
[No Abstract] [Full Text] [Related]
9. Risk of cardiovascular events associated with selective COX-2 inhibitors.
Mukherjee D; Nissen SE; Topol EJ
JAMA; 2001 Aug 22-29; 286(8):954-9. PubMed ID: 11509060
[TBL] [Abstract][Full Text] [Related]
10. COX-2 inhibitors. Magic bullets or merely mortal?
Harv Health Lett; 2000 Feb; 25(4):4. PubMed ID: 10637015
[No Abstract] [Full Text] [Related]
11. [Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine].
Krüger K
Z Rheumatol; 2001 Dec; 60(6):481-4. PubMed ID: 11826746
[No Abstract] [Full Text] [Related]
12. The coxibs, selective inhibitors of cyclooxygenase-2.
FitzGerald GA; Patrono C
N Engl J Med; 2001 Aug; 345(6):433-42. PubMed ID: 11496855
[No Abstract] [Full Text] [Related]
13. [Therapeutic advances with coxibs: few certainties and a lot of doubts].
Jouzeau JY; Daouphars M; Netter P
Therapie; 2004; 59(2):207-11. PubMed ID: 15359614
[No Abstract] [Full Text] [Related]
14. A tale of two coxibs.
Hegmann T
JAAPA; 2005 Mar; 18(3):14, 17. PubMed ID: 15789666
[No Abstract] [Full Text] [Related]
15. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
16. [Coxibs, which real therapeutic advance?: Recent pharmacoepidemiological data].
Montastruc JL; Lapeyre-Mestre M; Gony M; Lugardon S; Bagheri H
Therapie; 2004; 59(2):201-5. PubMed ID: 15366126
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the renal and cardiovascular safety of celecoxib and rofecoxib.
Schoors D
Clin Ther; 2002 Mar; 24(3):468-9; author reply 469-70. PubMed ID: 11952030
[No Abstract] [Full Text] [Related]
18. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
Howes LG; Krum H
Drug Saf; 2002; 25(12):829-35. PubMed ID: 12241124
[TBL] [Abstract][Full Text] [Related]
19. [New anti-inflammatory analgetics--are they needed?].
Paakkari I
Duodecim; 1999; 115(20):2217-24. PubMed ID: 11973925
[No Abstract] [Full Text] [Related]
20. Cardiovascular events and COX-2 inhibitors.
Fleming M
JAMA; 2001 Dec; 286(22):2808; author reply 2811-2. PubMed ID: 11735742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
